STRATEC Biomedical Systems AG / Contract 10.07.2008 Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- STRATEC to develop Bio-Rads next generation blood virus testing analyzer system Birkenfeld, July 10, 2008 STRATEC Biomedical Systems AG, Birkenfeld, Germany, signed an exclusive agreement with Bio-Rad Laboratories, Inc., Hercules, California, US, concerning the development and supply of a new family of analyzer systems, which will automate current and future generations of Bio-Rad's blood virus diagnostic tests. Bio-Rad and STRATEC launched a project in January 2008 to develop the new analyzer system. Further details concerning the cooperation are subject to a confidentiality agreement signed between the two parties. About Bio-Rad Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,300 people globally and had revenues approaching USD 1.5 billion in 2007. For more information, visit http://www.bio-rad.com. About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange. The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestr. 37, 75217 Birkenfeld Germany Phone: +49 7082 7916 190 Fax: +49 7082 7916 999 Email: ir@stratec-biomedical.de DGAP 10.07.2008 --------------------------------------------------------------------------- Language: English Issuer: STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: info@stratec-biomedical.de Internet: www.stratec-biomedical.de ISIN: DE0007289001 WKN: 728900 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Stuttgart, München, Düsseldorf End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-News: STRATEC to develop Bio-Rad's next generation blood virus testing analyzer system
| Source: EQS Group AG